에 대한 최신 뉴스 Bruker (NASDAQ:BRKR) 주식

Bruker

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.

News

Movers

ANET

ASML

BRKR

COIN

JBHT

MSTR

TSLA

지난주 이들 11개 대형주는 최하의 성과를 보여주었다. 여러분이 보유한 포트폴리오에도 이들이 있나요? Arm 홀딩스(NASDAQ:ARM)는 지난주 가장 성과가 나쁜 대형주 기업으로 31.08% 폭락했다. 이 회사의 주가는 ASML 홀딩 N.V. (NASDAQ:ASML)이 예상보다 저조한 1분기 연간 실적 발표에 영향을 받았다.

지난주 최하 성과 주식: 이 11개의 대형주가 포트폴리오에 있나요?

Bruker Corp

DFLI

Dragonfly Energy Signs Memorandum Of Understanding With Bruker To Collaborate And Improve Current And Next-Generation Battery Technology And Battery Materials

Bruker Reveals EpicIFTM, Revolutionary Fluorescence Signal Removal Technology, Transforming CellScape Spatial Proteomics Platform

Bruker Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) posted better-than-expected third-quarter results, but lowered <a href="https://www.benzinga.com/quote/BRKR/earnings">its FY24 guidance on Tuesday.</a>
Bruker posted adjusted earnings of 60 cents per share, beating market estimates of 59 cents per share. The company posted sales of $864.400 million versus expectations of $859.384 million.
Frank H. Laukien, Bruker&#8217;s President and CEO, commented, &#8220;Despite biopharma and China recovery delays, orders for our differentiated post-genomic, multiomics, cleantech, semicon and diagnostics solutions are gradually improving, with upper mid-single digit BSI organic bookings growth in Q3 year-over-year. However, nascent biopharma and China recoveries will not benefit our fiscal year 2024 anymore, and accordingly we are lowering our FY2024 guidance. Integrating and improving our strategic acquisitions is making good progress and will further accelerate Bruker&#8217;s remarkable transformation. We are confident in our ability to drive above-market organic revenue growth with significant margin expansion in 2025.&#8221;
Bruker shares fell 1.9% to trade at $60.15 on Wednesday.
These analysts made changes to their price targets on Bruker following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6554fd65a571ee0001ec9bce/terence-malone">Barclays analyst Terence Malone</a> maintained Bruker with an Overweight and lowered the price target from $75 to $69.</li>
<li>Wells Fargo analyst Brandon Couillard maintained Bruker with an Overweight and lowered the price target from $78 to $75.</li>
<li>TD Cowen analyst Dan Brennan maintained the stock with a Hold and lowered the price target from $72 to $70.</li>
<li>Citigroup analyst Patrick Donnelly maintained Bruker with a Buy and cut the price target from $80 to $75.</li>
</ul>
Considering buying BRKR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06140559/image-60-1024x576.png" alt="" class="wp-image-633525" style="width:667px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06140559/image-60-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06140559/image-60-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06140559/image-60-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06140559/image-60.png 1157w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41775237/amazon-disney-dupont-leidos-and-a-financial-stock-on-cnbcs-final-trades">Amazon, Disney, DuPont, Leidos And A Financial Stock On CNBC&#8217;s &#8216;Final Trades&#8217;</a></li>
</ul>

Earnings

Price Target

Markets

Analyst Ratings

Bruker Analysts Cut Their Forecasts After Q3 Results

Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Buy and lowers the price target from $80 to $75.

Citigroup Maintains Buy on Bruker, Lowers Price Target to $75

TD Cowen analyst Dan Brennan maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Hold and lowers the price target from $72 to $70.

TD Cowen Maintains Hold on Bruker, Lowers Price Target to $70

Wells Fargo analyst Brandon Couillard maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $78 to $75.

Wells Fargo Maintains Overweight on Bruker, Lowers Price Target to $75

Providing a diverse range of perspectives from bullish to bearish, 3 analysts have published ratings on Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $74.0, along with a high estimate of $78.00 and a low estimate of $69.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.33%. 
<img src="https://www.benzinga.com/files/images/story/2024/1730905212_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Bruker by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terence Malone</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Terence Malone</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$75.00</td>
<td>-</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$78.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bruker. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Bruker's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Bruker's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bruker analyst ratings.</a>
<h2>Delving into Bruker's Background</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.
<h3>Bruker: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Bruker's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.42% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Bruker's net margin is impressive, surpassing industry averages. With a net margin of 0.95%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Bruker's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.47%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.15%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Bruker's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.27, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 3 Analyst Evaluations For Bruker

Barclays analyst Terence Malone maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $75 to $69.

Barclays Maintains Overweight on Bruker, Lowers Price Target to $69

General

Bruker shares are trading lower after the company lowered its FY24 adjusted EPS and revenue guidance.

Fiscal Year 2024 (FY 2024) Financial Outlook
For FY 2024, Bruker now expects revenues of $3.34 to $3.37 billion, compared to FY 2023 revenues of $2.96 billion, with 12.5% to 13.5% year-over-year reported revenue growth, including:
<ul>
<li>Organic revenue growth of 3% to 4%,</li>
<li>Contribution from M&amp;A of approximately 9.5%,</li>
<li>Foreign currency translation impact approximately neutral,</li>
<li>CER revenue growth of approximately 13%.</li>
</ul>
Bruker now expects FY 2024 non-GAAP EPS of $2.36 to $2.41, compared to FY 2023 non-GAAP EPS of $2.58.

Guidance

Bruker Sees FY24 Adj. EPS $2.36-$2.41 (Prior $2.59-$2.64) vs $2.59 Est., Revenues $3.34B-$3.37B (Prior $3.38B-$3.44B) vs $3.40B Est.

Earnings Beats

Bruker Q3 2024 Adj. EPS $0.60 Beats $0.59 Estimate, Sales $864.400M Beat $859.384M Estimate

Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) will release its quarterly earnings report on Tuesday, 2024-11-05. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Bruker to report an earnings per share (EPS) of $0.61.
Investors in Bruker are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company missed EPS by $0.02, leading to a 2.99% drop in the share price the following trading session.
Here's a look at Bruker's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.54</td>
<td>0.46</td>
<td>0.68</td>
<td>0.63</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.52</td>
<td>0.53</td>
<td>0.70</td>
<td>0.74</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-0.0%</td>
<td>4.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730736246_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Bruker were trading at $59.29 as of November 01. Over the last 52-week period, shares are up 1.68%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Bruker</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Bruker.
Analysts have provided Bruker with 3 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $75.0, suggesting a potential 26.5% upside.
<h3>Peer Ratings Overview</h3>
The below comparison of the analyst ratings and average 1-year price targets of Charles River, Medpace Hldgs and Repligen, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Charles River received a Neutral consensus from analysts, with an average 1-year price target of $200.92, implying a potential 238.88% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Medpace Hldgs, with an average 1-year price target of $375.71, suggesting a potential 533.68% upside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Repligen, with an average 1-year price target of $192.5, indicating a potential 224.68% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary outlines pivotal metrics for Charles River, Medpace Hldgs and Repligen, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bruker</td>
<td>Outperform</td>
<td>17.42%</td>
<td>$384.60M</td>
<td>0.47%</td>
</tr>
<tr>
<td>Charles River</td>
<td>Neutral</td>
<td>-3.19%</td>
<td>$353.71M</td>
<td>2.44%</td>
</tr>
<tr>
<td>Medpace Hldgs</td>
<td>Neutral</td>
<td>8.29%</td>
<td>$169.01M</td>
<td>11.72%</td>
</tr>
<tr>
<td>Repligen</td>
<td>Outperform</td>
<td>-3.20%</td>
<td>$76.76M</td>
<td>0.17%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Bruker ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.
<h3>Discovering Bruker: A Closer Look</h3>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.
<h3>Financial Milestones: Bruker's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Bruker's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.42% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Bruker's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 0.95%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Bruker's ROE excels beyond industry benchmarks, reaching 0.47%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Bruker's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.15% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Bruker's debt-to-equity ratio surpasses industry norms, standing at 1.27. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/BRKR/earnings">To track all earnings releases for Bruker visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Bruker's Earnings Forecast

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54137544&amp;newsitemid=20241017641053&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=530321542f67933615f7393d4ba8458f">Bruker Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced that the European Unified Patent Court (UPC) has ruled in favor of its NanoString business, invalidating European Patent No. 2794928B1 (the "928 Patent"), which has been asserted by 10x Genomics against NanoString's CosMx&#xAE; Spatial Molecular Imager (SMI) products in Europe. Today's ruling follows the May 2024 decision of the German Federal Patent Court, which declared the 928 Patent invalid and revoked the patent in Germany. An appeal is pending in that case. Today's decision of the UPC expands on that German invalidity ruling to further invalidate the 928 Patent in France and The Netherlands. The ruling of the UPC is subject to appeal.

Legal

NSTGQ

European Unified Patent Court Rules In Favor Of Bruker And NanoString, Invalidating Patent Asserted By 10x Genomics Against NanoString's CosMx SMI Products

Barclays analyst Terence Malone initiates coverage on Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight rating and announces Price Target of $75.

Initiation

Barclays Initiates Coverage On Bruker with Overweight Rating, Announces Price Target of $75

Health Care

Bruker Announced The Formation Of A New Division, Bruker Spatial Biology Bringing Together In The Two Businesses Of NanoString Technologies And Canopy Biosciences, Along With Its Subsidiary Bruker Spatial Genomics (Formerly Acuity Spatial Genomics)

Bruker Corporation&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brkr#NASDAQ">BRKR</a>) recently announced the acquisition of Dynamic Biosensors GmbH, or DBS, a pioneering company known for its development in biosensors. The acquisition is aimed at boosting Bruker&#39;s biophysical portfolio, which is used for analyzing molecular interactions and kinetics. Financial details of the transaction were not disclosed.
Hence, the latest strategic acquisition is expected to strengthen Bruker&#39;s position in the pharma and biotech industries. The acquisition will leverage Bruker&#39;s leading high-throughput Surface Plasmon Resonance (&quot;SPR&quot;) portfolio and Dynamic Biosensors&#39; unique instruments.
<h2>BRKR&#39;s Likely Stock Trend Following the News</h2>
Subsequent to the news, the share price of BRKR moved north 1% to $67.46 on Wednesday. The company is gaining a high level of synergies from its continuous effort to reinforce its leading position within the pharma and biotech industries. Given the latest acquisition announcement, we expect market sentiment toward BRKR stock to continue to remain positive.
BRKR currently has a market capitalization of $9.97 billion. The company has a trailing four-quarter average earnings surprise of 10.09%.
<h2>Significance of Bruker&#39;s Latest Acquisition</h2>
DBS develops and markets innovative technologies for studying complex molecular interactions and kinetics to support drug discovery in the pharma and biotech industries, as well as in basic and medical research. The new Dynamic Biosensor heliX&nbsp;instrument performs single-cell Interaction Cytometry (scIC) for kinetic measurements directly on cells, retaining the molecules&#39; native membrane environment. Bruker&#39;s SPR portfolio includes all new SPR #64 &lsquo;Triceratops&#39;, and the 24 and 32-spot Sierra-Pro SPR systems.
The Bruker SPR portfolio is a great match for DBS&#39;s products. Hence, following the acquisition, the combined Bruker Biosensors business will offer one of the most innovative ranges of instruments, workflows, and consumables for studying intermolecular and molecule-cell interactions in the drug discovery pipeline. The acquisition should help Bruker establish itself as a new technology leader in biosensors with a differentiated offering.
In fiscal 2025, Bruker expects its Biosensors business to have an additional revenue gain of more than $5 million from the DBS acquisition, with no material EPS impact.
<h2>Other Recent Developments by Bruker</h2>
In August, Bruker completed the installation and acceptance of a 1.2 GHz Avance NMR spectrometer at the Korea Basic Science Institute (&quot;KBSI&quot;). As the first 1.2 GHz NMR system in the Asia-Pacific region, it sets a new benchmark for molecular, cell biology and disease research using ultra-high-field NMR.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/a8/80555.jpg?v=1793157732" />
Image Source: Zacks Investment Research
The same month, the company announced a strategic investment in&nbsp;NovAliX &mdash; a preclinical Contract Research Organization specializing in expert drug discovery services. Bruker&#39;s partnership with NovAliX should enable both companies to accelerate the development, incubation, deployment and support of advanced biophysical methods. The collaboration will leverage Bruker&#39;s leading post-genomic solutions competencies, combined with NovAliX&#39;s expert services and innovation.
<h2>Industry Prospects Favor Bruker</h2>
Per a Grand View Research report, the global biosensors market was valued at $28.9 billion in 2023 and is expected to witness a compound annual growth rate of 8.0% from 2024 to 2030. The demand for biosensors is increasing due to the diversity of medical applications, the increasing number of diabetic patients, the high demand for compact diagnostic devices and rapid technological improvement.
<h2>BRKR&#39;s Price Performance</h2>
In the past year, BRKR&#39;s shares have risen 6% compared with the industry&#39;s 23.8% growth.&nbsp;
<h2>BRKR&#39;s Zacks Rank and Key Picks</h2>
BRKR currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are TransMedics Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>), AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) and OrthoPediatrics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kids#NASDAQ">KIDS</a>). While TransMedics sports a Zacks Rank #1 (Strong Buy) at present, AxoGen and OrthoPediatrics carry a Zacks Rank #2 (Buy) each.
Estimates for TransMedics&#39; 2024 earnings per share have moved up 0.8% to $1.22 in the past 30 days. Shares of the company have soared 189.3% in the past year compared with the industry&#39;s 20.7% growth. TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for AxoGen&#39;s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 212.1% in the past year compared with the industry&#39;s 20.7% growth. AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for OrthoPediatrics&#39; 2024 loss per share have declined to 92 cents from 96 cents in the past 30 days. In the past year, shares of KIDS have lost 5.8% against the industry&#39;s 20.7% growth. In the last reported quarter, it delivered an earnings surprise of 25.81%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.81%.
<a href="https://www.zacks.com/stock/news/2347087/bruker-stock-gains-from-its-latest-acquisition-of-dynamic-biosensors?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2347087">To read this article on Zacks.com click here.</a>

Large Cap

Mid Cap

Offerings

Small Cap

Events

Trading Ideas

AXGN

KIDS

TMDX

Bruker Stock Gains From Its Latest Acquisition of Dynamic Biosensors

October 7th, 2024: Bruker BioSpin Group today announced the acquisition of the Electron Paramagnetic Resonance (EPR) business of Bridge12, a Massachusetts-based company (<a href="http://www.bridge12.com/">www.bridge12.com</a>). With Bridge12's solutions for certain cutting-edge research using EPR technology, Bruker further enhances its suite of EPR spectroscopy offerings.
Bridge12 offers modular EPR bridges for pulsed spectroscopy, high-field EPR spectrometers for multi-frequency experiments, microwave amplifiers, and EPR probes. Their innovative technology and collaborative research initiatives aim to advance EPR spectroscopy, providing superior versatility in EPR instrumentation.

Bruker Strengthens EPR Offerings, Acquires Bridge12's Advanced Spectroscopy Technology, Financial Terms Undisclosed

Bruker Corporation&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brkr#NASDAQ">BRKR</a>) growth is backed by strong sales within its X-Ray and Nano Analytics businesses. Within the PCI division, expanding customer demand for pre-clinical MRI systems is highly encouraging. Meanwhile, the impact of macroeconomic pressure and currency fluctuation is likely to hurt the company&#39;s operational results.
In the past year, this Zacks Rank #3 (Hold) company&#39;s shares have gained 10.4% compared with the industry&#39;s 27.5% growth and the S&amp;P 500 composite&#39;s 34.9% gain.
This renowned medical device company has a market capitalization of $11.77 billion. It has a 2025 earnings growth rate of 17.6%, which is much higher than the industry&#39;s 13.8% growth rate. BRKR&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.1%.
Let&#39;s delve deeper.
<h2>Bruker&#39;s Key Upsides</h2>
Bright Prospects Within Nano Business Segment:&nbsp;The segment caters to a large set of customers, such as academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses that are involved in materials research and life science research analysis. The business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.&nbsp;
During the first half of 2024, the company&#39;s advanced X-Ray and Nano Analytics businesses delivered strong sales, backed by Nano&#39;s robust revenue growth. Nano&#39;s strong growth is driven by the rising demand in academic and government markets. The Nanostring acquisition is expected to be both strategically and financially beneficial, promising a high return on investment for Bruker.
The Potential of Preclinical Imaging (PCI) Market: Per Grand View Research, the global PCI market was valued at $4.30 billion in 2023 and is likely to witness a CAGR of 4.6% up to 2030. Therefore, this translates into a golden opportunity for Bruker to expand its foothold in the PCI market and earn higher profits from this division.
Bruker offers advanced PCI solutions for a broad spectrum of application fields. Moreover, this division is experiencing increasing customer demand for higher-strength pre-clinical magnetic resonance imaging systems. Earlier this year, Bruker filled a critical gap in its PCI portfolio with the acquisition of Spectral Instruments Imaging LLC, a leader in preclinical in-vivo optical imaging systems.
<h2>Bruker&#39;s Key Downsides</h2>
Unfavorable Currency Movement: Bruker generates a substantial portion of its revenues in the international markets, primarily in Germany and other countries in the European Union, Switzerland and Japan.&nbsp; As a result, currency fluctuations continue to result in foreign currency transaction losses for the company. In addition, currency fluctuations are likely to cause the price of Bruker&#39;s products to be less competitive than its principal competitors&#39; offerings.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6e/80173.jpg?v=35874249" />
Image Source: Zacks Investment Research
Macroeconomic Factors:&nbsp;Present global economic challenges and uncertainties have made it harder for Bruker to manage operations and predict financial outcomes. Geopolitical conditions are impacting its operational results. In addition, supply-chain risks also persist. All these issues are leading to higher costs and expenditures for the company, impacting its profitability.
In the second quarter, Bruker&#39;s cost of revenues increased 21.6% from the same period in 2023. SG&amp;A expenses surged 24.4%.
<h2>BRKR&#39;s Estimate Trend</h2>
The Zacks Consensus Estimate for Bruker&#39;s 2024 earnings per share remained unchanged at $2.61 for the past 30 days.
The consensus estimate for the company&#39;s 2024 revenues is pegged at $3.41 billion, indicating a 14.9% rise from the year-ago &nbsp;number.
<h2>Key Picks</h2>
Some better-ranked stocks in the broader medical space are&nbsp;TransMedix Group&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>),&nbsp;AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) and Phibro Animal Health (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>).
TransMedix Group&#39;s earnings are expected to surge 255.8% in 2024. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%. Shares of the company have risen 173.5% in the past year compared with the industry&#39;s 22.4% growth. TMDX sports a Zacks Rank #1 (Strong Buy) at present.
AxoGen, carrying a Zacks Rank #2 (Buy) at present, has an earning yield of 94.1% compared with the industry&#39;s 12.3%. Shares of the company have risen 194.6% compared with the industry&#39;s 22.3% growth over the past year.&nbsp;AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.46%.
Phibro, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 21% for fiscal 2025 compared with the industry&#39;s 12.6%. In the past year, shares of PAHC have risen 72.7% compared with the industry&#39;s 25.2% growth. PAHC delivered a trailing four-quarter average earnings surprise of 4.10%.
<a href="https://www.zacks.com/stock/news/2345297/here-s-why-you-should-retain-brkr-stock-in-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2345297">To read this article on Zacks.com click here.</a>

Macro Economic Events

Economics

PAHC

Here's Why You Should Retain BRKR Stock in Your Portfolio Now

This acquisition strengthens Bruker&#39;s biophysical portfolio for the analysis of molecular interactions and kinetics, offering deeper insights into both inter-molecular and molecule-single cell interactions in drug discovery or basic research.
In FY2025, Bruker Biosensors expects additional revenues greater than&nbsp;$5 million&nbsp;from the DBS acquisition, with no material EPS impact.

Bruker Acquires Germany-Based Dynamic Biosensors GmbH; Financial Details Not Disclosed

In the last three months, 4 analysts have published ratings on Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $72.5, along with a high estimate of $80.00 and a low estimate of $60.00. This current average has decreased by 9.75% from the previous average price target of $80.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1727701209_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Bruker among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$78.00</td>
<td>-</td>
</tr>
<tr>
<td>Max Masucci</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$72.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$60.00</td>
<td>$72.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bruker. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bruker's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bruker analyst ratings.</a>
<h2>All You Need to Know About Bruker</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.
<h3>Unraveling the Financial Story of Bruker</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Bruker showcased positive performance, achieving a revenue growth rate of 17.42% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Bruker's net margin excels beyond industry benchmarks, reaching 0.95%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Bruker's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.47% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Bruker's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.15% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Bruker's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.27, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 4 Ratings For Bruker

BofA lowered the firm's price target on Bruker (BRKR) to $78 from $79 and keeps a Buy rating on the shares. Bruker's Q3 results came in below estim...

Bruker price target lowered to $78 from $79 at BofA

TD Cowen analyst Daniel Brennan maintained a Hold rating on Bruker (BRKR – Research Report) today and set a price target of $70.00. Daniel Brennan'...

Bruker: Navigating Challenges with a Balanced Hold Rating Amid Sector Headwinds and Recovery Opportunities

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ardelyx (ARDX – Research Report), Ultragenyx Pharmac...

Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Ultragenyx Pharmaceutical (RARE) and Bruker (BRKR)

Barclays analyst Luke Sergott lowered the firm's price target on Bruker (BRKR) to $69 from $75 and keeps an Overweight rating on the shares. The co...

Bruker price target lowered to $69 from $75 at Barclays

In a report released yesterday, Brandon Couillard from Wells Fargo maintained a Buy rating on Bruker (BRKR – Research Report), with a price target ...

Bruker: Attractive Valuation and Strategic Positioning Support Buy Rating

Citi lowered the firm's price target on Bruker (BRKR) to $75 from $80 and keeps a Buy rating on the shares post the Q3 report. Bruker saw ongoing s...

Bruker price target lowered to $75 from $80 at Citi

TD Cowen analyst Dan Brennan lowered the firm's price target on Bruker (BRKR) to $70 from $72 and keeps a Hold rating on the shares. The firm said ...

Bruker price target lowered to $70 from $72 at TD Cowen

Leerink Partners analyst Puneet Souda has maintained their bullish stance on BRKR stock, giving a Buy rating yesterday. Puneet Souda has given his ...

Bruker Buy Rating: Strategic Positioning and Recovery Potential Amid Pharma Sector Challenges

Dragonfly Energy (DFLI) announced it has signed a Memorandum of Understanding, MOU, with Bruker (BRKR) to collaborate and significantly improve cur...

Dragonfly Energy, Bruker partner to accelerate battery tech development

Life sciences stocks viewed positively at TD Cowen despite post-election weakness

ADPT

ARDX

AVTR

EXAS

ILMN

MDXH

MYGN

NTRA

PACB

RARE

RVTY

Press Releases

Bruker Introduces Innovative Neuroscience Research Solution with High-Speed OptoVolt Voltage Imaging

Bruker Announces Formation of New Bruker Spatial Biology Division

Biotech

Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications at the HUPO World Congress

European Unified Patent Court Rules in Favor of Bruker and NanoString, Invalidating Patent Asserted By 10x Genomics against NanoString's CosMx SMI Products

Bruker Announces One-Hundred Dollar, Deep, High-Accuracy Plasma Proteome; Advances Glycoproteomics and Metaproteomics

Bruker Announces Date and Time of Third Quarter 2024 Earnings Release and Webcast

Bruker Reports Third Quarter 2024 Financial Results

Bruker Announces EpicIFTM, Revolutionary Fluorescence Signal Removal Technology, Transforming CellScape Spatial Proteomics Platform

Dragonfly Energy and Bruker Partner to Accelerate Battery Technology Development

Bruker Corporation to Present at Upcoming Investor Conferences

DFLIW

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Fortrea Holdings

Illumina

IQVIA Hldgs

Medpace Hldgs

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

Citigroup

TD Cowen

Wells Fargo

Barclays

지난주 이들 11개 대형주는 최하의 성과를 보여주었다. 여러분이 보유한 포트폴리오에도 이들이 있나요?
<ol>
<li>Arm 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)는 지난주 가장 성과가 나쁜 대형주 기업으로 31.08% 폭락했다. 이 회사의 주가는 ASML 홀딩 N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)이 예상보다 저조한 <a href="https://www.benzinga.com/news/24/04/38299189/whats-going-on-with-arm-holdings-stock" target="_blank" rel="noreferrer noopener">1분기 연간 실적 발표</a>에 영향을 받았다. 엑산 BNP 파리바(Exane BNP Paribas)의 데이비드 오코너(David O&#8217;Connor) 분석가는 ARM의 목표 가격을 100달러로 유지하며 등급을 <a href="https://www.benzinga.com/quote/ARM/analyst-ratings" target="_blank" rel="noreferrer noopener">&#8220;시장 수익률 상회(Outperform)&#8221;에서 &#8220;중립(Neutral)&#8221;으로 </a>하향 조정했다.</li>
<li>마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주가는 지난주 20.07% 하락했다. 반감기를 앞둔 비트코인(CRYPTO:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/btc-usd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BTC/USD">BTC</a>) 가격의 변동성때문에 지난주 대부분의 암호화폐 주식이 하락했다.</li>
<li>코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주식은 비트코인(CRYPTO:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/btc-usd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BTC/USD">BTC</a>) 가격의 약세로 인해 지난주 15%의 빠졌다. 경제학자인 피터 쉬프(Peter Schiff)는 일부 강세 예측에 맞춰 이 암호화폐가 상승할 것에 대해 회의적인 입장을 <a href="https://www.benzinga.com//node/38265256" target="_blank" rel="noreferrer noopener">표명했</a>다.</li>
<li>프롤로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>)의 주식은 13.73% 하락했다. 이 회사의 2024년 1분기 임대 수익은 18억 3천만 달러로 컨센서스를 하회했으며 예상되는 <a href="https://www.benzinga.com/news/earnings/24/04/38292399/why-prologis-shares-are-trading-lower-today" target="_blank" rel="noreferrer noopener">평균 점유율 감소와 경쟁적 임대</a>로 인해 EPS 및 핵심 FFO/주식에 대한 FY24 전망을 낮췄다.</li>
<li>테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 주식은 지난주 13.6% 하락했다. 일론 머스크가 이끄는 이 회사는 <a href="https://www.benzinga.com//node/38346490" target="_blank" rel="noreferrer noopener">여러 이유로</a> 힘든 1주일을 보냈다. 현재 하락하는 전기차 수요, 사이버트럭 리콜, 직원 감축 및 가격 인하에 직면하고 있다.</li>
<li>에퀴팩스(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/efx" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for EFX">EFX</a>)의 주식은 13.54% 빠졌다. 이 회사는 예상보다 나쁜 1분기 판매 실적을 보고했으며 수요일에 <a href="https://www.benzinga.com/news/earnings/24/04/38333254/equifax-analysts-cut-their-forecasts-after-q1-results" target="_blank" rel="noreferrer noopener">추정치보다 낮게 조정된 지침</a>을 발표했다.</li>
<li>브루커 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>)의 주식은 현금 3억 9,260만 달러 나노스트링 테크놀로지스(NanoString Technologies)의 인수를 발표한 후 주가가 11.90% 하락하는 등 힘든 한 주를 보냈다.</li>
<li>라이브 네이션 엔터테인먼트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>)는 11.76% 하락했다. 이 회사의 주식은 법무부가 해당 회사를 상대로 독점 금지 <a href="https://www.benzinga.com/news/24/04/38265894/live-nation-entertainment-groupon-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session" target="_blank" rel="noreferrer noopener">소송을</a> 제기할 것이라는 보도가 나오면서 주가는 하락세를 보였다.</li>
<li>아리스타 네트웍스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>)의 주가는 지난주 10.69% 하락했다. 최근 로젠블라트(Rosenblatt)의 분석가는 목표 가격 210달러로 주식을 &#8220;매도&#8221;로 <a href="https://www.benzinga.com//node/38220808" target="_blank" rel="noreferrer noopener">두 단계</a>  하향 조정했다.</li>
<li>J.B. 헌트 트랜스포트 서비스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/jbht" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for JBHT">JBHT</a>)의 주가는 지난주 10.47% 하락했다. 1분기 수익은 하위 부문 <a href="https://www.benzinga.com/news/earnings/24/04/38287679/why-j-b-hunt-transport-shares-are-diving-today" target="_blank" rel="noreferrer noopener">총 매출 감소와 선적 감소</a>로 인해 컨센서스 예상치를 밑돌았다. 몇몇 분석가들은 실적 부진 이후 <a href="https://www.benzinga.com/quote/JBHT/analyst-ratings" target="_blank" rel="noreferrer noopener">주식 목표 가격</a>을 낮췄다.</li>
<li>앨버말(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)의 주식은 지난주 리튬 가격의 변동성으로 인해 9%의 가치를 잃었다.</li>
</ol>
참고 자료: <a href="https://www.benzinga.com/news/earnings/24/04/38349264/tracking-last-weeks-top-performers-are-these-7-large-cap-stocks-in-your-portfolio" target="_blank" rel="noopener">지난주 최고 성과 추적: 이 7개의 대형주가 포트폴리오에 포함되어 있나요?</a>
사진: 셔터스톡

Comments

Bruker

뉴스

에 대한 최신 뉴스 Bruker (NASDAQ:BRKR) 주식

월요일, 4월 22, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌